Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
73 results about "Immunologic disease" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An immunological disease results from the disorder of the immune system. It may fall into one of these categories: allergic diseases, autoimmune diseases, immune complex diseases, and immunodeficiency disorders. Allergic Diseases The most common types of allergic diseases occur when the immune system responds to a false alarm.
Detection and treatment of autoimmune disorders
Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing the involving a PD1 ligand.
Owner:SEATTLE CHILDRENS HOSPITAL
Novel tricyclic protein kinase modulators
InactiveUS20110071136A1Good treatment effectReduce cell proliferationBiocideSenses disorderInflammationImmunologic disease
The invention provides compounds that inhibit CK2 and / or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
Owner:SENHWA BIOSCIENCES INC
Autoimmune disease biomarkers
InactiveUS20080254482A1Convenient treatmentAntipyreticAnalgesicsSide effectAutoimmune thyroid disease
Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease.
Owner:INVITROGEN
Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
InactiveUS20130150559A1Strong upregulationImmunoglobulin superfamilyImmunoglobulins against cell receptors/antigens/surface-determinantsAutoimmune conditionDc maturation
Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
Owner:NOVO NORDISK AS
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
InactiveUS20060193821A1Inhibit functioningInhibit bindingOrganic active ingredientsNervous disorderAutoimmune conditionAutoimmune disease
The present invention provides materials and methods to treat immune disease in which cytokines are involved in pathogenesis. The materials and methods of the present invention are useful in the treatment of autoimmune diseases. The materials and methods of the present invention are directed to nucleic acid ligands capable of binding to human IL-23 and / or human IL-12 cytokines and thus modulate their biological activity and are useful as therapeutic agents in immune, auto-immune and cancer therapeutics.
Owner:ARCHEMIX CORP
Agent for treating disease
ActiveUS20110059082A1Easy to manageIncrease doseNervous disorderAntipyreticRegulatory T cellAutoimmune condition
The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.
Owner:OGEN GMBH
Tumor necrosis factor alpha
InactiveUS20070037164A1Raise the possibilityDelay and reduce and preventSugar derivativesMicrobiological testing/measurementFactor iiTumour necrosis factor alpha
The present disclosure describes the use of genetic variance information for genes involved in inflammatory or immunologic disease, disorder, or dysfunction. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.
Owner:NUVELO INC
Compositions and methods for treatment of autoimmune and allergic diseases
InactiveUS20110143994A1Reduce the possibilityPreventing”, “prophylaxis”Senses disorderNervous disorderEpitopeAutoimmune responses
The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically the invention relates to new immuno-modulating complexes which are fusion proteins comprising mutant subunits of bacterial endotoxins, a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease.
Owner:TOLERANZIA
Antagonist of th-1 immunerresponse inducing cytokine for the treatment of autoimmune diseases
Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition of prevention of autoimmune diseases.
Owner:PHARM PACIFIC PTY LTD
Thienopyrazole Derivative Having PDE7 Inhibitory Activity
To provide thienopyrazole derivatives inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic diseases, inflammatory diseases or immunologic diseases. The compound is thienopyrazole compound represented by the following formula (I):[wherein, especially, R1 is a cyclohexyl, a cycloheptyl group or a tetrahydropyranyl group; R2 is methyl; R3 is a hydrogen atom; and R4 is a group: —CONR5R6 (in which any one of R5 and R6 is a hydrogen atom)].
Owner:DAIICHI SANKYO CO LTD
Treatment of autoimmune inflammation using mir-155
InactiveUS20120064122A1Decreasing CD4+ T cell proliferationReduces production of cytokineAntibacterial agentsOrganic active ingredientsDendritic cellAutoimmune disease
The present disclosure relates to the finding that microRNA-155 plays a role in the development and activity of CD4+ T cells. CD4+ T cell development and function, particularly TH17 and TH1 T cell development, can be modulated by delivery of microRNA-155 (miR-155) or antisense miR-155 to target CD4+ cells or precursor cells. In some embodiments, antisense miR-155 is used to reduce tissue specific autoimmune inflalmmation and to treat autoimmune disease. In addition, miR155 and antisense miR-155 can be used to modulate expression of cytokines from dendritic cells.
Owner:CALIFORNIA INST OF TECH
Isoflavones compound and preparation and application thereof
ActiveCN101648937AEnhanced inhibitory effectOrganic active ingredientsOrganic chemistrySide effectTreatment interval
The invention discloses a novel isoflavones compound as shown by a formula I. The results of animal experiments show that the isoflavones compound can significantly inhibit the proliferation of T cells and B cells, and can be used for preparing immunosuppressants or medicaments for treating immunologic diseases. The SI values (IC50 / CC50) of the isoflavones compound are high, so the toxic side effects of the isoflavones compound are small, and the treatment interval of the isoflavones compound is wide. The isoflavones compound is obtained by extracting and separating clovershrubs, and the preparation method is simple and convenient.
Owner:BASILEA PHARM CHINA LTD
Kit for detecting antinuclear antibody spectrum related to autoimmune diseases (AIDs)
ActiveCN102937648AOriginalityPlay the role of interpretationMaterial analysisAntigenAutoimmune condition
The invention relates to a kit for detecting antinuclear antibody spectrum related to AIDs. The kit comprises a membrane strip, enzyme-labeled liquid, a substrate and concentrating and washing incubation liquid, wherein the membrane strip is composed of a carrier piece and an antigen band, a critical quality control band and a functional quality control line which are sequentially fixed on the carrier piece. The antigen band is composed of at least two of dsDNA, nucleosomes, SmD1, ribosome P0proteins, histones, U1snRNP, Ro / SS-A(52KD), Ro / SS-A(60KD), La / SS-B, Sc1-70, CENP-B, Jo-1, AMA-M2, PM-Sc1, PCNA, Mi-2 and Ku through independent marking to a nitrocellulose membrane or a nylon membrane. The kit is provided with the ingenious critical quality control band, one critical quality control band can play a role in interpreting two or even more detection bands (antigen bands), and result determination is simpler and more reliable.
Owner:SICHUAN XINCHENG BIOLOGICAL CO LTD
Estriol therapy for autoimmune and neurodegenerative disease and disorders
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.
Owner:RGT UNIV OF CALIFORNIA
Glycotargeting therapeutics
ActiveUS20200129625A1Lower immune responseImprove the level ofPeptide/protein ingredientsAllergen ingredientsAutoimmune conditionAntiendomysial antibodies
Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1 / Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.
Owner:OSAKA UNIV
Immune response suppressor and treatment of multiple sclerosis
ActiveUS20070185030A1Improve the level ofSlow onsetPeptide/protein ingredientsMetabolism disorderSoluble immune response suppressorAutoimmune condition
The present invention provides methods of treating multiple sclerosis, type 1 diabetes mellitus and other autoimmune diseases by administering a soluble immune response suppressor (SIRS) peptide or a variant thereof to an individual having such disease. The SIRS peptide or variant reduces the severity of or frequency of relapse of multiple sclerosis and reduces the inflammation associated with multiple sclerosis and other autoimmune diseases.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Recombination Sequence (RS) Rearrangement Frequency as a Measure of Central B Cell Tolerance
ActiveUS20110182902A1Increased riskLower Level RequirementsOrganic active ingredientsSugar derivativesTolerabilityAutoimmune responses
The invention relates to methods and materials for diagnosing an autoimmune disease such as SLE, Type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (RS) rearrangement as a novel marker for an autoimmune disease. Such an assay can allow clinicians to diagnose an autoimmune disease based on the RS rearrangement frequency in an autoimmune patient as compared to an otherwise healthy control. In addition, the method includes identifying individuals who are at increased risk of developing autoimmunity. The method may also be helpful in directing the type of therapy and monitoring the effects of therapy in patients with autoimmune or non-autoimmune conditions.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Specific activation of a regulatory t cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction
ActiveUS20100074904A1Improve clinical pictureStrong proliferationSenses disorderVirusesTolerance inductionRegulatory T cell
The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
Owner:ACTITREXX GMBH
5-benzylidene-2,4-thiazolidinedione derivatives and preparation method and application thereof
InactiveCN101973957AConvenient treatmentOrganic active ingredientsOrganic chemistryThiazolidinedioneStereochemistry
The invention belongs to the field of chemical medicines, and in particular relates to 5-benzylidene-2,4-thiazolidinedione derivatives and a preparation method and application thereof. Aiming at solving the first technical problem, the invention provides a new series of 5-benzylidene-2,4-thiazolidinedione derivatives shown in a formula I, which has he function of treating immunologic diseases.
Owner:SICHUAN UNIV
Methods for predicting autoimmune disease risk
InactiveUS20120003228A1Optimized predictive modelAccurate predictionOrganic active ingredientsNervous disorderVaccinationVasculitis
The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject. Autoimmune diseases of particular interest include vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The invention also relates to means and methods for determining the CD8 or CD4 cell subtype of a subject, e.g. for predicting responses to infection, vaccination and / or transplantation.
Owner:CAMBRIDGE ENTERPRISE LTD
Glycotargeting therapeutics
ActiveUS10953101B2Lower immune responseImprove the level ofPeptide/protein ingredientsAllergen ingredientsAutoimmune conditionAntiendomysial antibodies
Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Coumaronochromones compound and preparation and application thereof
ActiveCN101648959ASimple methodSuitable for industrial productionOrganic chemistrySkeletal disorderImmunologic disordersLymphocyte
The invention discloses a coumaronochromones compound as shown by a formula 1. Pharmacological experiments show that the coumaronochromones compound has significant inhibitory action on the proliferation of B lymphocytes and T lymphocytes, and can be used for preparing immunosuppressive agents or medicaments for treating various immunologic diseases such as rheumatoid arthritis, lupus erythematosus and the like, and the medicaments for treating B cell type chronic lymphocytic leukemia. The invention also provides a preparation method.
Owner:BASILEA PHARM CHINA LTD
Immunologic activity measures for t helper on-associated conditions
InactiveUS20060216716A1Accurately reflectAddressing slow performanceMicrobiological testing/measurementPeptidesWhite blood cellStimulant
A method of providing a reproducible and clinically relevant disease activity measurement for a group of immunologic disorders that share features of a T “helper” 1 (Th1) immune activation phenotype is disclosed. Th1 responses are characterized by the release of a set of pro-inflammatory substances by white blood cells (WBC) By evaluating the ex vivo activation response of whole blood in terms of the extent of release of Th1 produced pro-inflammatory substances in blood (i.e., WBC activity) following activation with a Th1-associated stimulant, the level of, e.g., disease activity or immunosuppression in a specific individual can be determined. The method of the invention provides a disease activity marker for a wide variety of Th1 inflammatory responses, including Crohn's Disease, psoriasis, rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), multiple sclerosis and solid organ transplant rejection.
Owner:SAUBERMANN LAWRENCE J +2
Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1 / Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.
Owner:OSAKA UNIV
Ligands of hvem for treating hematologic malignancies and autoimmune diseases
ActiveUS20100196386A1Low immunogenicityStrong cytotoxicityNervous disorderPeptide/protein ingredientsChronic lymphatic leukemiaGackstroemia
The present invention relates to ligands of HVEM for the treatment of hematologic malignancies, in particular Chronic lymphocytic leukaemia, and for the treatment of autoimmune diseases.
Owner:OLIVE +1
HDAC inhibiting derivatives of camptothecin
InactiveUS8980909B2Improve efficacyIncreased toxicityBiocideSilicon organic compoundsDiseaseHydroxamic acid
Owner:CRYSTAL BIOPHARML LLC
Limonoids for treating autoimmune diseases
The invention relates to an application of limonoids in preparation of medicine for treating autoimmune diseases, wherein the limonoids include a structure represented as the formula (I), wherein R isoptionally selected from hydroxylated alkyl groups. The invention further relates to an application of the limonoids in preparation of a medicine for inhibiting differentiation of T-helper cell 17, and an application of the limonoids in preparation of a medicine for inhibiting differentiation of T-helper cell 1, T-helper cel 2 or regulative T cells. A method of screening substances capable of inhibiting cells of one or more of Th17, Th1, Th2 and Treg, which can be used for treating the autoimmune diseases. The limonoids can inhibit the differentiation of the Th17, Th1, Th2 and / or Treg cells.
Owner:MACAU UNIV OF SCI & TECH
Transforming growth factor beta 1 (TGFbeta1) haplotypes and prediction of susceptibility for immunological disorders
InactiveUS20060024706A1Inhibit inflammationDecrease airway hyper reactivitySugar derivativesPeptide/protein ingredientsRisk haplotypeGenetic analysis
The present invention is related to the haplotypes of human Transforming Growth Factor Beta1 (TGFβ1) and prediction of susceptibility for immunological disorders. More particularly the present study is the first study in any population, identifying novel protective and risk haplotypes of the TGFβ1 gene The present invention also relates to allelic variants of the human Transforming Growth Factor Beta1 (TGFβ1) gene. The said invention also provides primers and methods suitable for the detection of these haplotypes and allelic variants for the prediction of an individual's disease susceptibility, and / or the genetic analysis of the TGFβ1 gene for immunological disorders, particularly asthma. A vital aspect of the present study provides a method for predicting susceptibility of individuals to immunological disorders, particularly asthma.
Owner:COUNCIL OF SCI & IND RES
Medicinal application of A type proanthocyanidin trimer polyphenol
The invention discloses medicinal application of A type proanthocyanidin trimer polyphenol. The medicinal application is that the A type proanthocyanidin trimer polyphenol is taken as one of active compositions or the only one active composition to prepare medicine preparations for treating immunologic diseases. Experiments show that the half cell lethal concentration of the A type proanthocyanidin trimer polyphenol is larger than 50 mu g / mL, and the A type proanthocyanidin trimer polyphenol has inhibiting effect on propagation of lymphocyte induced by mitogen ConA and secretion of cytokines IL-6 and IFN-gamma important for immunoloregulation and inflammation reactions, is expected to be taken as one of active compositions or the only one active composition for preparing medicine preparations for treating immunologic diseases, especially is expected to be taken as one of active compositions or the only one active composition for preparing medicine preparations for treating rheumatoid arthritis, and has medicinal value.
Owner:SHANGHAI UNIV OF T C M
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com